

Product datasheet for **TL313016**

Fukutin (FKTN) Human shRNA Plasmid Kit (Locus ID 2218)

Product data:

Product Type:	shRNA Plasmids
Product Name:	Fukutin (FKTN) Human shRNA Plasmid Kit (Locus ID 2218)
Locus ID:	2218
Synonyms:	CMD1X; FCMD; LGMD2M; LGMDR13; MDDGA4; MDDGB4; MDDGC4
Vector:	pGFP-C-shLenti (TR30023)
E. coli Selection:	Chloramphenicol (34 ug/ml)
Mammalian Cell Selection:	Puromycin
Format:	Lentiviral plasmids
Components:	FKTN - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 2218). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.
RefSeq:	NM_001079802 , NM_001198963 , NM_006731 , NM_001351496 , NM_001351497 , NM_001351498 , NM_001351499 , NM_001351500 , NM_001351501 , NM_001351502 , NR_147213 , NR_147214 , NM_001079802.1 , NM_006731.1 , NM_006731.2 , NM_001198963.1 , BC117699 , BC058842 , BC101808 , BC112038 , BC117700 , NM_001198963.2 , NM_001079802.2
UniProt ID:	O75072
Summary:	The protein encoded by this gene is a putative transmembrane protein that is localized to the cis-Golgi compartment, where it may be involved in the glycosylation of alpha-dystroglycan in skeletal muscle. The encoded protein is thought to be a glycosyltransferase and could play a role in brain development. Defects in this gene are a cause of Fukuyama-type congenital muscular dystrophy (FCMD), Walker-Warburg syndrome (WWS), limb-girdle muscular dystrophy type 2M (LGMD2M), and dilated cardiomyopathy type 1X (CMD1X). Alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Nov 2010]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).